RT Journal Article
T1 Glutaminase isoenzymes in the metabolic 1 therapy of cancer
A1 Mates-Sánchez, José Manuel
A1 Campos-Sandoval, José Ángel
A1 Márquez-Gómez, Javier
K1 Cáncer - Aspectos moleculares
K1 Antiangiogénicos
AB Altered cellular metabolism is a hallmark of cancer. Cancer cells express isoforms of metabolic enzymes that may constitute therapeutic targets. Glutaminase controls glutamine metabolism and their expression correlate with malignancy of tumours. The two types of glutaminase isoenzymes, GLS and GLS2, differ in their expression patterns and functional roles: GLS has oncogenic properties and GLS2 has been described as a tumour suppressor factor. Selective genomic and epigenomic intervention over glutaminase affects the metabolic reprogramming of cancer. This review highlights the molecular metabolic vulnerabilities in various types of cancer, to be used for biomarker development, drug design, and in personalized oncology.
PB Elsevier
YR 2018
FD 2018-07
LK https://hdl.handle.net/10630/37401
UL https://hdl.handle.net/10630/37401
LA eng
NO José M. Matés, José A. Campos-Sandoval, Javier Márquez, Glutaminase isoenzymes in the metabolic therapy of cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1870, Issue 2, 2018, Pages 158-164, ISSN 0304-419X, https://doi.org/10.1016/j.bbcan.2018.07.007. (https://www.sciencedirect.com/science/article/pii/S0304419X1830101X)
NO Mensaje de la editorial Elsevier:Dear Dr. José A. Campos-Sandoval,I have attached the accepted version of your manuscript for your reference. Kindly check and let me know if you need any further assistance. Best regards,NarmathaJournal Manager
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026